Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 4 Triple Negative Breast Neoplasms 3 Neoplasm Metastasis 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Lung Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Bevacizumab 112 Fluorouracil 98 Oxaliplatin 96 Leucovorin 96 Irinotecan 86 Capecitabine 73 Cetuximab 64 Panitumumab 42 pembrolizumab 38 regorafenib 28 Nivolumab 23 IFL protocol 22 Folfox protocol 21 trifluridine tipiracil drug combination 14 Radiotherapy 13 durvalumab 11 Gemcitabine 10 Celecoxib 10 tremelimumab 7 binimetinib 7 aflibercept 7 Drug Therapy 7 Disulfides 7 Cyclophosphamide 7 Trifluridine 6 Trastuzumab 6 Sunitinib 6 Paclitaxel 6 Immunoglobulin G 6 Colonoscopy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Colorectal Neoplasms × trilaciclib × Clear all

NCT04607668 2024-11-26

PRESERVE1

G1 Therapeutics, Inc.

Phase 3 Terminated

326 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡